PCSK9 and ENaC in nephrotic syndrome in ma

Withdrawn

• Conditions: nephrotic syndrome; protein losing illness; 10029149

• Registration Number: NL-OMON51030
• Lead Sponsor: Rijnstate Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- Presence of heavy proteinuria (>3.5g/24h)
- Presence of hypoalbuminemia (<30g/L)
- Presence of peripheral edema, based on clinical assessment of the treating
physician
- Presence of hypercholesterolemia (LDL cholesterol >3.0 mmol/L)
- Age >=18 years

Exclusion Criteria

- Use of immunosuppressive drugs
- Estimated glomerular filtration rate (eGFR) of <15, as calculated by the
chronic
kidney disease epidemiology collaboration (CKD-epi) formula
- Serum potassium of >5.0 mmol/L
- Blood pressure of <120/80 mmHg
- Unable to give informed consent
- Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is serum LDL cholesterol</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>ENaC activity assessed by urine Na/K ratio</p><br>